In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy According to Analysts.
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence. Investors are finding these tendencies appealing, especially in early-stage biotech firms with cutting-edge drug pipelines.
According to a June 4 CNBC article, global biopharma mergers and acquisitions are predicted to reach their highest level since the pre-pandemic peak seven years ago. According to PitchBook data, dealmaking has already exceeded $106 billion via 201 transactions in 2026. By year’s end, the sector is predicted to be close to $250 billion if the current enthusiasm persists. The average deal value has increased to $527.3 million from $365 million in 2025 as pharmaceutical companies accelerate acquisitions to strengthen their pipelines and prevent approaching patent expirations.
Oncology, metabolic disease, and central nervous system medicines have drawn a lot of attention, and strategic acquisitions in the $1 billion to $5 billion area have dominated activity. The biotech ETF index XBI has gained more than 50% over the last 12 months as the IPO market has reopened, thanks to the strengthening market environment, which has also improved investor optimism.
On June 9, 2026, Reuters revealed that Parabilis Medicines had raised its U.S. IPO from 25 million to 33.3 million shares, aiming for a valuation of up to $2.3 billion. This was a clear indication of this recovery. More than 150 patients have received doses of the company’s top candidate, zolucatetide, which is presently being tested for various solid tumors. Reuters reported on June 8, 2026, that Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash to extend its oncology pipeline through the company’s protein-degrading platform targeting KRAS-driven malignancies, demonstrating the continued strength of consolidation.
With that said, let’s take a look at the best biotech stocks.
Our Methodology
For our methodology, we screened for biotech stocks with an analyst upside of at least 20%. From this list, we selected companies with the most recent news and developments and ranked them in ascending order based on their analyst upside as of June 24.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Here is our list of the 10 best biotech stocks to buy according to analysts.
10. MapLight Therapeutics, Inc. (NASDAQ:MPLT)
Price Target Upside: 25.16%
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the best biotech stocks on this list.
TheFly reported on June 24 that Raymond James initiated coverage of MPLT with a Strong Buy rating and a $46 price target. The firm highlighted Cobenfy as a significant advancement in schizophrenia treatment but noted challenges related to treatment persistence. Raymond James sees potential upside ahead of the Phase 2 ZEPHYR trial readout for ML-007C-MA, expected by mid-August. The firm also identified MPLT’s Alzheimer’s disease psychosis program as a potential value driver, despite limited investor attention toward Alzheimer ’s-focused opportunities.
Separately, on June 22, MapLight Therapeutics, Inc. announced topline findings from its Phase 2 IRIS trial evaluating ML-004 in autism spectrum disorder (ASD). The study enrolled 161 participants and assessed multiple measures, including social communication and irritability outcomes. While the trial did not achieve its primary endpoint related to social communication improvement at Week 12, a prespecified analysis showed ML-004 produced clinically meaningful improvements in irritability among adolescents with moderate or higher baseline irritability compared with placebo. The treatment also demonstrated positive trends on clinician-rated irritability measures. ML-004 was generally well tolerated, with mostly mild-to-moderate adverse events and no severe safety concerns reported in treated participants.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for central nervous system disorders using advanced neurotechnologies.
9. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Price Target Upside: 33.72%
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list.
TheFly reported on June 16 that Canaccord analyst Whitney Ijem increased the price target on RYTM to $151 from $143 while maintaining a Buy rating. The update followed a positive interim review from the Phase 2 study of setmelanotide in Prader-Willi syndrome (PWS). Canaccord highlighted continued BMI improvements with longer treatment exposure, with reductions reaching 3.06% at six months compared with 1.84% at three months. The firm also noted that 8 of 10 patients with moderate to severe baseline hyperphagia achieved a clinically meaningful reduction of at least 7 points on the HQ-CT assessment.
On June 15, Rhythm Pharmaceuticals, Inc. announced new data presentations from ENDO 2026 highlighting results from its MC4R agonist programs in acquired hypothalamic obesity, Bardet-Biedl syndrome, and Prader-Willi syndrome. The company reported positive findings showing improvements in weight-related outcomes and hyperphagia across multiple patient populations. Data included long-term setmelanotide results in acquired hypothalamic obesity, real-world outcomes in BBS patients, and Phase 2 results in PWS. The findings supported the potential of MC4R pathway therapies to address rare neuroendocrine disorders with limited treatment options and demonstrated continued progress across RYTM’s development programs.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company developing precision medicines for rare genetic obesity and neuroendocrine disorders.
8. MoonLake Immunotherapeutics (NASDAQ:MLTX)
Price Target Upside: 41.38%
MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list.
TheFly reported on June 22 that Clear Street maintained its Buy rating and $70 price target on MLTX. The firm highlighted SLK’s potential in hidradenitis suppurativa following the company’s investor event focused on the therapy’s development and commercialization strategy. Clear Street noted that SLK’s profile in HS remains highly competitive and could support a significant commercial opportunity. The firm also stated that the Biologics License Application submission remains expected by September 30, with management continuing to view the possibility of priority review.
Moreover, on June 23, MoonLake Immunotherapeutics announced the pricing of its underwritten public offering, including 9 million Class A ordinary shares at $20.00 per share and pre-funded warrants for up to 1 million additional shares at $19.9999 per warrant. The offering is expected to generate approximately $200 million in gross proceeds before fees and expenses. MLTX also provided underwriters with a 30-day option to purchase an additional 1.5 million Class A ordinary shares. The company plans to use the proceeds to support research, development, pre-commercialization, and commercialization activities for sonelokimab, if approved, and general corporate purposes.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for inflammatory skin and joint diseases, led by Sonelokimab, a next-generation IL-17 inhibitor.
7. Definium Therapeutics, Inc. (NASDAQ:DFTX)
Price Target Upside: 43.73%
Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best biotech stocks on this list.
TheFly reported on June 23 that Robert W. Baird analyst Christopher Chen increased the price target on DFTX to $57 from $37 while maintaining an Outperform rating. The update followed the company’s Emerge trial results, which prompted the firm to revise its valuation model.
Separately, on June 22, Definium Therapeutics, Inc. announced positive topline findings from the Emerge Phase 3 study evaluating DT120 ODT 100 microgram as a single-dose treatment in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in depressive symptoms based on the change in MADRS total score at Week 6. Patients receiving DT120 ODT recorded an LS mean MADRS change of -13.3 compared with -5.2 for placebo, resulting in an LS mean difference of -8.1 points. The treatment also demonstrated rapid activity, with a placebo-adjusted LS mean reduction of -14.2 points at Week 1, and maintained durable effects with a -7.3-point reduction at Week 12.
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation therapies for psychiatric and neurological disorders using psychedelic and psychoplastogenic medicine.
6. Zymeworks Inc. (NASDAQ:ZYME)
Price Target Upside: 46.57%
Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list.
TheFly reported on June 9 that Truist Securities initiated coverage of ZYME with a Buy rating and a $28 price target, down from $40. The firm highlighted ZYME as a balanced investment opportunity, supported by its royalty-based business model and expanding oncology pipeline that could provide long-term growth potential. Truist also pointed to pipeline assets, including Pasritamig in metastatic castration-resistant prostate cancer, as potential contributors due to upcoming clinical milestones.
Separately, on June 14, Zymeworks Inc. presented updated clinical findings from the dose-escalation phase of its ongoing Phase 1 trial assessing ZW191, an antibody-drug conjugate targeting folate receptor alpha. The data were presented at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. Results showed encouraging anti-tumor activity in platinum-resistant ovarian cancer patients across different FRalpha expression levels. ZW191 achieved a confirmed objective response rate of 78.6% in FRalpha-positive patients and 47.4% in FRalpha-negative patients across evaluated dose levels. Median duration of response had not yet been reached, while median progression-free survival was 7.6 months across ovarian and endometrial cancer groups. Dose optimization enrollment was completed, with tolerability results supporting further clinical development.
Zymeworks Inc. is a clinical-stage biotechnology company developing next-generation cancer therapies, including multispecific antibodies and antibody-drug conjugates (ADCs).
5. Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Price Target Upside: 63.74%
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list.
TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the shares. The firm noted that Barzolvolimab’s Phase 3 chronic spontaneous urticaria (CSU) program has a favorable development outlook and could support a potential approval in 2027.
In addition to that, more recently, on June 14, Celldex Therapeutics, Inc. presented updated long-term findings from its Phase 2 study of barzolvolimab during a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. The results showed that barzolvolimab provided rapid and sustained improvements in angioedema symptoms among patients with chronic spontaneous urticaria who had not responded adequately to antihistamine treatment. The benefits remained evident seven months after patients completed dosing, highlighting the potential durability of the treatment effect. The findings further support barzolvolimab’s ability to move CSU treatment beyond symptom management toward disease modification and reinforce continued evaluation in ongoing Phase 3 CSU trials.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody therapies for inflammatory and autoimmune diseases, led by barzolvolimab for mast cell–driven conditions.
4. Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Price Target Upside: 69.67%
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best biotech stocks on this list.
TheFly reported on June 18 that Baird increased its price target on NRIX to $33 from $26 while maintaining an Outperform rating on the shares. The firm adjusted its valuation to account for the company’s partnership with Roche and continued progress across its clinical programs.
Separately, earlier on June 11, Nurix Therapeutics, Inc. reported updated clinical findings from its ongoing NX-5948-301 Phase 1a/b trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data showed continued durable responses in heavily pretreated patients along with encouraging activity in earlier treatment settings. Across 142 Phase 1a/b CLL patients, bexobrutideg demonstrated a favorable safety profile, with no dose-limiting toxicities or treatment-related Grade 5 adverse events. In relapsed/refractory CLL patients, the therapy achieved an objective response rate of 83% with a median progression-free survival of 22.1 months. Earlier-line cohorts also showed strong activity, including ORRs of 92.9% and 84.2% in evaluated groups. The results support further development of bexobrutideg, including a planned Phase 3 monotherapy program.
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies and other treatments for cancer and autoimmune diseases.
3. Jade Biosciences, Inc. (NASDAQ:JBIO)
Price Target Upside: 104.82%
Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the best biotech stocks on this list.
TheFly reported on June 15 that UBS initiated coverage of JBIO with a Buy rating and a $45 price target. The firm highlighted JADE101 as the company’s lead program, viewing it as a potential best-in-class therapy in the $20 billion IgA nephropathy market. UBS noted that JADE101 could reach a peak sales potential of approximately $3 billion to $4 billion. The firm also believes the IgA nephropathy market can support multiple successful treatments rather than being dominated by a single therapy.
In addition to that, earlier on June 1, Jade Biosciences, Inc. announced positive interim findings from its Phase 1 study of JADE101, an investigational anti-APRIL monoclonal antibody being developed for immunoglobulin A nephropathy (IgAN). The trial evaluated JADE101’s safety, tolerability, pharmacokinetics, and pharmacodynamic effects in 32 healthy volunteers across four dose groups. Results showed approximately 70% reductions in IgA levels sustained through 12 weeks at the 700 mg dose, along with strong APRIL suppression and a favorable safety profile. JADE101 was well tolerated at doses up to 1,400 mg, with no serious adverse events reported. The company advanced JADE101 into Phase 2 development and plans a Phase 3 trial in the first half of 2027.
Jade Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal antibody therapies for autoimmune and inflammatory diseases, including treatments targeting APRIL pathways in IgAN.
2. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Price Target Upside: 139.49%
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks on this list.
TheFly reported on June 14 that at ENDO 2026, CRNX presented Phase 2 data from its TouCAHn study evaluating investigational atumelnant in adults with classic congenital adrenal hyperplasia (CAH). The open-label trial assessed the once-daily oral ACTH receptor antagonist candidate, which is being developed for classic CAH and ACTH-dependent Cushing’s syndrome. Results from Cohort 4 showed that atumelnant enabled glucocorticoid dose reductions while maintaining androgen control. At week 12, participants experienced a 67% average reduction in morning serum androstenedione levels, with 7 of 8 patients reaching physiologic glucocorticoid dosing. The therapy was generally well tolerated, with no treatment-related severe or serious adverse events reported. The findings support continued development of atumelnant in later-stage clinical trials.
On the same day, it was reported that Crinetics Pharmaceuticals, Inc. presented updated long-term data from its PALSONIFY (paltusotine) clinical development program in acromegaly at ENDO 2026. Pooled results from the open-label extension studies of PATHFNDR-1 and PATHFNDR-2 showed that once-daily oral PALSONIFY maintained disease control and was well-tolerated after two years of treatment. In PATHFNDR-1, patients previously controlled on injectable SRLs maintained stable IGF-1 levels, symptoms, and tumor volume. PATHFNDR-2 showed reductions in IGF-1 levels among patients with uncontrolled acromegaly, with stable symptoms and tumor measurements. Across the pooled population of 167 patients, no new safety concerns were identified.
Crinetics Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company developing novel treatments for rare endocrine diseases, including PALSONIFY (paltusotine), an approved therapy for related conditions.
1. Ascentage Pharma Group Internat (NASDAQ:AAPG)
Price Target Upside: 182.19%
Ascentage Pharma Group Internat (NASDAQ:AAPG) is one of the best biotech stocks on this list.
TheFly reported on June 15 that Oppenheimer initiated coverage of AAPG with an Outperform rating and a $45 price target. The firm highlighted the company’s recent clinical presentations, including two oral presentations on olverembatinib at ASCO and early clinical findings from APG-115. Oppenheimer also noted AAPG’s previously reported year-end financial position, with $353 million in cash expected to fund operations through 2027.
On June 14, Ascentage Pharma Group Internat announced that seventeen clinical updates from its core programs were presented at the European Hematology Association (EHA2026) Congress, including eight poster presentations. The data highlighted ongoing studies of olverembatinib (HQP1351) and lisaftoclax (APG-2575) across multiple hematologic malignancies. Olverembatinib demonstrated sustained clinical activity in chronic myeloid leukemia (CML), including patients with TKI resistance, while updated results from the POLARIS-1 Phase 3 study supported its potential in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax data from CLL/SLL studies provided additional insights into treatment strategies, with real-world findings also showing clinical utility in myeloid neoplasms. The company continues advancing global development of these therapies and exploring combination treatment approaches.
Ascentage Pharma Group Internat is a global clinical-stage biotechnology company developing innovative therapies for cancer, chronic hepatitis B, and age-related diseases.
READ NEXT: 10 Best Future Stocks to Buy and Hold for 10 Years and 10 Most Promising Long-Term Stocks to Buy According to Analysts.
Hedge Fund Resource Center